ObsEva gets funding and makes deal with Merck Serono

30 August 2013

Geneva, Switzerland-based ObsEva says that it has closed a 32 million Swiss franc ($34.8 million) -A financing round, led by Sofinnova Partners and co-led by Sofinnova Ventures and Novo A/S.

Concurrently, ObsEva signed a licensing agreement with Germany’s Merck KGaA’s (MRK: DE) biotech unit, under which Merck Serono will grant ObsEva worldwide development and commercialization rights to certain of its compounds in the field of preterm labor. The details of the agreement are not being disclosed. The funding will allow ObsEva to undertake the development of these compounds.

As part of the deal, MS Ventures, the corporate venture capital fund of Merck Serono, has taken a minority equity stake in the company.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical